Synopsis:- Stocks gained up to 8% after bulk deals highlighted shifting ownership. Strategic buying worth Rs 74 crore contrasted with stake sales of Rs 64 crore, while transactions involving 20 lakh and 48 lakh shares signaled active institutional participation and evolving investor sentiment in the market.
A bulk deal refers to a large transaction of shares executed on the stock exchange, typically involving at least 0.5% of a company’s equity. These deals are carried out during market hours and disclosed publicly, offering insights into investor sentiment, institutional activity, and potential shifts in ownership patterns.
Indian benchmark indices extended gains in late morning trade, with the Sensex rising over 400 points and the Nifty climbing above 24,450, supported by strength in PSU banks and energy stocks.
Bharat Wire Ropes
Bharat Wire Ropes Ltd is a leading manufacturer of wire ropes, catering to sectors like infrastructure, mining, oil & gas, and construction. The company is known for its advanced manufacturing facilities and strong product quality, enabling it to serve both domestic and international markets while benefiting from rising infrastructure development. With a market capitalisation of Rs 1,639 crore, the shares were trading at Rs 239 crore, increasing around 8 percent as compared to the previous closing price.
As per the exchange, Lloyds Metals and Energy acquired 20 lakh shares at Rs 193.42 per share, while Lloyds Enterprises bought 11.46 lakh shares at Rs 215.17 and 5 lakh shares at Rs 215, taking a combined 5.31% stake worth Rs 74.11 crore, indicating a strong strategic interest.
However, as per the exchange, Resonance Opportunities Fund exited 17.02 lakh shares (2.48% stake) at Rs 193 per share, amounting to Rs 32.84 crore. This partial exit contrasts with Lloyds Group’s entry, suggesting a shift in shareholding from institutional investors to strategic buyers.
Ind-Swift Laboratories
Ind-Swift Laboratories Ltd operates in the pharmaceutical and biotechnology space, focusing on active pharmaceutical ingredients (APIs) and formulations. With a presence in global markets, the company emphasises research, manufacturing efficiency, and regulatory compliance, positioning itself to benefit from growing demand in the healthcare and generics industry. With a market capitalisation of Rs 1,216 crore, the shares were trading at Rs 140 crore, increasing around 6.06 percent as compared to the previous closing price.
As per the exchange, HCP Investments sold 48 lakh shares (5.53% stake) in Ind-Swift Laboratories at Rs 134.18 per share, totalling Rs 64.4 crore, following an earlier 1.12% sale. This brings total divestment to 6.65% over two sessions, significantly reducing its holding from 8.65% as of February 24, 2026.
However, as per the exchange, buying interest emerged with Sahastraa Advisors acquiring 4.75 lakh shares at Rs 131.74 per share, while Nova Global Opportunities Fund PCC – Touchstone picked up 8.03 lakh shares at Rs 138.07. This indicates partial absorption of supply by institutional investors, balancing the sharp stake reduction.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
